ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AVR / insiders
ZJYL (46) ENOV (38) SMTI (55) CDRE (62) ⌘ Pro Terminal →

Anteris Technologies Global Corp. (AVR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$6.31 -1.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.28

Anteris Technologies Global Corp. (AVR) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $615.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AVR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AVR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Anteris Technologies Global Corp. (NASDAQ: AVR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $6.31 (-1.71% 1D, market cap $615.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, AVR ranks #958 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AVR compare to ZJYL and ENOV in the Health Care sector?
▼

Within the Health Care sector (Industrial Specialties), AVR carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 70.3%, and ROIC of -35.0%. By comparison, ZJYL (JIN MEDICAL INTERNATIONAL LTD. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $371.8M) and ENOV (Enovis Corporation) posts a D- grade (38/100 RQD, P/E N/A, ROIC -32.7%, cap $1.15B). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AVR?
▼

Per AVR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002011514), Anteris Technologies Global Corp. generated $1.9M in revenue (-29.2% YoY), -$94.1M in net income, and -$79.8M in free cash flow against $23.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.28 (-0.50%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (22/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510022
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (7)Whales (4)SEC (5)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-16.2% Base Target
$12 Bull$5 Base$4 Bear
📬 FREE AVR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AVR)Realized 20D OHLCV Swing Band: ±9.9%
Deterministic 5-Pillar Attribution (22/100 Composite)
🔍 WHY AVR SCORES 22/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+7/20 pts (32% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 70.3% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
30
Grade E$6.45-2.5% Next Q
Q2 (-2Q)
27
Grade E$6.29-4.6% Next Q
Q3 (-1Q)
25
Grade E$6.00+5.2% Next Q
Current
22
Grade E$6.31-11.4% Hist 90D α
Trajectory: E (30) → E (22)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AVR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AVR currently carries a cautious 22/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.45) and Max Pain ($6.63) forces dealer call-delta covering toward $11.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AVR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AVR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 22%NO 78%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

AVR Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (AVR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on AVR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AVR)

  • ✓Walkthrough of AVR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AVR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.94%▼ DESCENDING CHANNEL
2026-11-03O $6.42H $6.42L $6.31C $6.31VOL 1.40M
RES: $8.51SUP: $5.54SMA50: $7.45SMA200: $7.40
$11.49$9.71$7.94$6.16$4.39RES $8.51SUP $5.54$6.312026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AVR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AVR Butterfly Map → + Track AVR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -29.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AVR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AVR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AVR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AVR)

Health Care Rank #958 of 1015 ⚔️ ZJYL vs AVR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AVR vs. ZJYL, ENOV, SMTI, CDRE)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Anteris Technologies Global Corp. (AVR) ranks #958 by composite RQD confidence (22/100, grade E) and #409 by equity capitalization ($615.2M). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. CDRE currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with AVR at 22/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AVR ACTIVE
Anteris Technologies Global Corp.
E 22/100 — 70.3% -35.0% -1.71% $615.2M Benchmark Subject
ZJYL
JIN MEDICAL INTERNATIONAL LTD. (Class A)
D 46/100 — 29.2% — +26.34% $371.8M /zjyl-vs-avr →
ENOV
Enovis Corporation
D- 38/100 — 59.8% -32.7% -12.71% $1.15B /enov-vs-avr →
SMTI
Sanara MedTech Inc.
D+ 55/100 8.1x 92.7% 16.3% -0.26% $301.6M /smti-vs-avr →
CDRE
Cadre Holdings Inc.
C 62/100 30.2x 42.5% 11.0% -2.38% $1.30B /cdre-vs-avr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002011514 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anteris Technologies Global Corp. (AVR) reported GAAP revenue of $1.9M (-29.2% vs. FY2024 revenue of $2.7M ) , GAAP net income of -$94.1M, operating cash flow of -$77.8M, and free cash flow of -$79.8M (-25.6% YoY). On the balance sheet, AVR closed FY2025 with $23.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.9M -$94.1M -$77.8M -$79.8M $23.0M —
FY2024 (FY) 2024-12-31 $2.7M -$76.3M -$61.2M -$63.5M $80.7M —

3. AVR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AVR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Anteris Technologies Global Corp. (NASDAQ: AVR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $6.31 (-1.71% 1D, market cap $615.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, AVR ranks #958 in composite RQD confidence.

How does AVR compare to ZJYL and ENOV in the Health Care sector?

Within the Health Care sector (Industrial Specialties), AVR carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 70.3%, and ROIC of -35.0%. By comparison, ZJYL (JIN MEDICAL INTERNATIONAL LTD. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $371.8M) and ENOV (Enovis Corporation) posts a D- grade (38/100 RQD, P/E N/A, ROIC -32.7%, cap $1.15B). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AVR?

Per AVR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002011514), Anteris Technologies Global Corp. generated $1.9M in revenue (-29.2% YoY), -$94.1M in net income, and -$79.8M in free cash flow against $23.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AVR trading relative to its 50-day, 200-day, and 52-week technical levels?

AVR last traded at $6.31 (-1.71% on volume of 1,396,960 shares), positioning the stock -15.30% below its 50-day simple moving average ($7.45) and -14.73% below its 200-day simple moving average ($7.40). Across its 52-week range of $3.30 to $11.06, AVR sits at the 38.8% percentile with a 14-day RSI of 41.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.9% ($5.69 to $6.93).

Direct Sub-Reports: AVR RQD Cockpit AVR 12M Forecast AVR Earnings & Move AVR Dividends & DRIP AVR Insiders & 13F AVR Whale Options AVR Profit Sankey AVR News & Why
ROARABLE RATING BRIEF • RQD 22/100 (E) ✓ SEC XBRL & RQD VERIFIED

AVR — Anteris Technologies Global Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Anteris Technologies Global Corp. (AVR) earns a live Roarable RQD composite score of 22/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $6.31 (-1.71% 1D, market capitalization $615.2M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 70.3%, operating margin of -60.0%, and free cash flow yield of -12.74%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Anteris Technologies Global Corp. (AVR) is a NASDAQ-listed issuer classified under the Health Care sector and Industrial Specialties industry. The source profile does not describe its specific products, customers, or revenue model. Reported revenue of $1.9M for FY 2025 and $2.7M for FY 2024 indicates a very small revenue base relative to its operating losses. Gross margin is reported at 70.3%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Anteris Technologies Global Corp. (AVR) reported $1.9M in annual revenue (up from $2.7M in FY2024, -29.2% YoY) and -$94.1M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($2.7M revenue, -$76.3M net income) through FY2025, AVR scaled operating cash flow to -$77.8M and free cash flow to -$79.8M, backed by $23.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 22/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -12.74% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $3.30 – $11.06 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations for AVR. Investors should note that the absence of recorded links is a data limitation, not evidence of independence. The second-order risk the data does make visible is funding-related: with FY 2025 cash at $6.7M against a -$79.8M free cash flow outflow, the company's ability to sustain operations without new capital is a central bottleneck, and any dilution or financing event would be a ripple to watch.

  • Key Question #1: Can AVR sustain or expand its -60.0% operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.9M and free cash flow of -$79.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is AVR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AVR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Anteris Technologies Global Corp. (AVR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AVR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AVR Bull vs. Bear Conversation Board — What's Your Call at $6.31?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AVR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AVR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $8.01 (+26.9%)
📌 Pinned Debate

Cantor Fitzgerald reiterated an Overweight rating, and a 10% owner's funds bought AVR shares on two October dates.

Cantor Fitzgerald reiterated an Overweight rating, and a 10% owner's funds bought AVR shares on two October dates.. When you look under the hood at AVR, Fundamental Cash Engine is 7/20 with 70.3% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (4/20) has been quietly accumulating below $11.06. My 12M target is $8.01.

SectorRotator 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Industrial Specialties. If gross margin (70.3%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $5.17 (-18.1%)
Spot @ $6.31

FY 2025 free cash flow was -$79.8M against only $6.7M of reported cash, with the RQD rating at 23/100 (Grade E).

FY 2025 free cash flow was -$79.8M against only $6.7M of reported cash, with the RQD rating at 23/100 (Grade E).. Look at the math on AVR: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Industrial Specialties demand softens. I'd wait for a retest of $5.55 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%